Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
A regulatory RNA molecule specific to immune T cells sustains metabolic balance and immune function in the aging liver, addressing a fundamental mechanism of age-related decline. This correction validates findings on how the body maintains coordinated immune and metabolic signaling during aging.
Sana Biotechnology's immune-evasive cell therapy (UP421) has demonstrated survival of transplanted insulin-producing cells without immunosuppressive medication in a first-in-human study, with transplanted cells responding dynamically to glucose levels after 14 months. This approach fundamentally reframes type 1 diabetes treatment from immune suppression to immune tolerance, with potential implications for regenerative medicine across multiple organ systems.
HRS-7535, an oral GLP-1 receptor agonist, demonstrated 11.1% weight loss at 44 weeks in Phase 3 trials with a favorable safety profile dominated by mild-to-moderate gastrointestinal effects. The drug also showed non-inferiority to dapagliflozin in type 2 diabetes management while producing larger HbA1c reductions, positioning it as an alternative to injectable agents in metabolic disease treatment.
Reproductive behaviors interact with genetic susceptibility to modulate aging trajectories, with certain lifestyle patterns amplifying or buffering age-acceleration risk in genetically predisposed individuals. This research identifies a modifiable behavioral layer that operates independently of genetic burden, suggesting that aging rate is not fixed by inheritance alone.
LG AI Research and D&D Pharmatech are partnering to use artificial intelligence to design peptide therapeutics, compressing the molecular discovery timeline by generating novel candidates based on pattern recognition rather than manual search. This collaboration addresses both the design challenge and the delivery barrier that has limited peptide drug development, positioning AI as an active research participant rather than a background tool.
BioAge has initiated Phase 2 testing of BGE-102, an NLRP3 inflammasome inhibitor, to assess whether reducing systemic inflammation improves cardiovascular outcomes in adults at elevated risk. The trial represents a shift in drug discovery methodology—identifying therapeutic targets through analysis of successful aging biology rather than disease pathology—potentially targeting a shared mechanism underlying multiple age-related conditions.
Sarcopenia and osteoporosis share bidirectional risk pathways mediated by inflammation, metabolic dysfunction, and genetic factors related to mitochondrial function and immune regulation. This integrated mechanism suggests that addressing muscle and bone loss requires simultaneous intervention on shared biological drivers rather than treating them as separate conditions.
RNA expression—not static DNA—reveals real-time shifts in how your body responds to food, stress, and environment. Combined with microbiome analysis and AI-driven interpretation of biomarkers, this approach enables personalized nutrition and health optimization rather than population-level dietary prescriptions that often fail at the individual level.
Pemvidutide, a dual glucagon/GLP-1 receptor agonist, demonstrated sustained reductions in cardiometabolic risk factors and liver fibrosis over 48 weeks in patients with metabolic dysfunction-associated steatohepatitis. This positions the compound as a potential therapeutic option in a therapeutic area where metabolic and hepatic dysfunction often progress in parallel.
Muscle mass and strength function as longevity biomarkers, with training stimulus and nutritional support directly influencing mortality risk across age groups. Optimization requires integrated approaches to movement patterns, protein synthesis, and recovery—not isolated interventions.
Sleep disruption in older African American and low-income adults stems from interconnected environmental, social, and physiological stressors rather than aging alone. Understanding these specific barriers—noise, housing instability, health burden, social isolation—is essential for tailoring interventions that address root causes rather than symptoms.
Metformin's cancer risk profile remains inconsistent across tumor types, with prostate cancer showing increased incidence in some populations while other malignancies show protective associations. This heterogeneity demands precision in how the drug is prescribed for metabolic optimization, as blanket recommendations obscure the mechanistic and epidemiological distinctions between different cancer contexts.